Report of Foreign Issuer (6-k)
October 31 2019 - 9:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of October 2019
001-36345
(Commission File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Attached hereto and incorporated herein
by reference is a press release, dated October 31, 2019, and entitled “Galmed Pharmaceuticals to Present New Data on Aramchol
effect on glucose metabolism, MoA and clinical results at AASLD 2019.”
The first paragraph and “Forward
Looking Statements” of the press release attached to this Form 6-K are incorporated by reference into the Company’s
Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement
on Form F-3 (Registration No. 333-223923).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
Galmed
Pharmaceuticals Ltd.
|
|
|
|
|
Date: October
31, 2019
|
By:
|
/s/ Allen Baharaff
|
|
|
|
Allen Baharaff
|
|
|
|
President and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024
